Genetic testing

Leading Reproductive Expert Dr. Eva Schenkman Takes Helm as Director of Embryology Services at Gattaca Genomics

Retrieved on: 
Tuesday, February 27, 2024
Embryology, Education, IVF, ELD, ABB, Genomics, Entrepreneurship, Andrology, ALD, Genetic testing

Fort Lauderdale, Florida, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Gattaca Genomics proudly appoints renowned scientist, Dr. Eva Schenkman, as the Director of Embryology Services.

Key Points: 
  • Fort Lauderdale, Florida, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Gattaca Genomics proudly appoints renowned scientist, Dr. Eva Schenkman, as the Director of Embryology Services.
  • Dr. Schenkman's appointment as Director of Embryology Services signifies Gattaca Genomics' commitment to attracting top-tier talent in the field.
  • In her capacity as Director of Embryology Services, Dr. Schenkman will leverage her extensive experience in IVF laboratory management, andrology, and embryology to lead Gattaca Genomics in pioneering advancements in reproductive health.
  • Michael Carbonara, CEO of Gattaca Genomics says, "Dr. Eva Schenkman's appointment is a testament to Gattaca Genomics' commitment to excellence.

Prevent Cancer Foundation awards $1 million in new research grants

Retrieved on: 
Wednesday, February 21, 2024
Head, Breast cancer, Neck, Cancer, Woman, Survivor, Diet, Reproductive medicine, Assistant, Melanoma, Blood, Uterus, Biostatistics, Skin, Immunodeficiency, Database, Communication, Risk, FACP, Breast, University, Stomach, Vaccination, MD Anderson Cancer Center, Member of Congress, Genetic, Dicarboxylic acid, Drinking, Ovarian cancer, Genetics, Squamous-cell carcinoma, Death, Associate, Genetic testing, Black, Huntsman Cancer Institute, SCCS, Disease, HPV, Knowledge, Health literacy, Mortality, New York University, Research, University of North Carolina, Partnership, Birth control

Alexandria, Va., Feb. 21, 2024 (GLOBE NEWSWIRE) -- The Prevent Cancer Foundation® is pleased to announce new funding for ten scientists who are researching cancer prevention and early detection.

Key Points: 
  • Alexandria, Va., Feb. 21, 2024 (GLOBE NEWSWIRE) -- The Prevent Cancer Foundation® is pleased to announce new funding for ten scientists who are researching cancer prevention and early detection.
  • Read on for more on the 2024 research grantees or access more detailed information on their projects in the researcher database.
  • Having a family history of cancer can affect the age at which cancer screening begins and genetic testing recommendations.
  • To view all past funded research grant and fellowship projects driving these key advancements in cancer prevention and early detection, explore the Prevent Cancer Foundation’s Award Database.

Myriad Genetics to Release Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024

Retrieved on: 
Wednesday, February 21, 2024
Genetics, Telephone, MYGN, PIN, Medicine, Genetic testing, Conference, Video game

SALT LAKE CITY, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will hold its fourth quarter earnings conference call on Tuesday, February 27, 2024 at 4:30p.m.

Key Points: 
  • SALT LAKE CITY, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will hold its fourth quarter earnings conference call on Tuesday, February 27, 2024 at 4:30p.m.
  • The company’s quarterly earnings will be released the same day after the market closes.
  • During the call, Myriad management will provide a financial overview and business update of the company’s performance for the fourth quarter and full year 2023.
  • The 44th Annual Cowen Health Care Conference with a fireside chat featuring Sam Raha, chief operating officer, and Ben Wheeler, chief financial officer – operations, on March 5, 2024, at 12:50pm EST.

GeneDx Reports Fourth Quarter and Full Year 2023 Financial Results and Issues Guidance for Full Year 2024

Retrieved on: 
Tuesday, February 20, 2024
Montefiore, VUS, Genetics in Medicine, Total, Legacy, Abraxis BioScience, Partnership, Exome, DSM-IV codes, WGS, Commercial, GAAP, American College, ACMG, Genome, Genetic testing, Medicaid, Genetics, Google Health, Medical genetics, Publication, NICU, Bank

ET

Key Points: 
  • ET
    STAMFORD, Conn., Feb. 20, 2024 (GLOBE NEWSWIRE) -- GeneDx Holdings Corp. (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today reported its financial results for the fourth quarter and full year of 2023.
  • Exome and genome represented 27% of all test results, up from 16% in the fourth quarter of 2022 and up from 23% in the third quarter of 2023.
  • Adjusted gross margin from continuing operations expanded to 56%, up from 41% in the fourth quarter of 2022 and up from 48% in the third quarter of 2023.
  • Excluding one-time items, representative continuing operations cash burn was $23.9 million in the fourth quarter of 2023.

Asia-Pacific Rare Disease Genetic Testing Market Analysis and Forecasts, 2023-2024 and 2033 - Opportunities in Transitioning Toward Increased Genetics Coverage in Reimbursement Policies - ResearchAndMarkets.com

Retrieved on: 
Thursday, March 7, 2024
Health, Genetics, Rare disease, Name, Growth, Exome, Genetic code, WES, WGS, Organization, Genetic testing, Medicine, Genome, Disease, Vaccine

The "Asia-Pacific Rare Disease Genetic Testing Market: Analysis and Forecast, 2023-2033" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Asia-Pacific Rare Disease Genetic Testing Market: Analysis and Forecast, 2023-2033" report has been added to ResearchAndMarkets.com's offering.
  • The Asia-Pacific (APAC) rare disease genetic testing market is witnessing notable growth driven by various factors.
  • What are the major market drivers, challenges, and opportunities in the Asia-Pacific rare disease genetic testing market?
  • What are the key development strategies implemented by the key players to stand out in the Asia-Pacific rare disease genetic testing market?

Global Metagenomic Market Research 2024-2028: A Game Changer in Diagnostics - New Technology Changes Viewpoint on Infections - ResearchAndMarkets.com

Retrieved on: 
Friday, March 1, 2024
Health Technology, Health, Medical Devices, Infection, Metagenomics, Chronic condition, Genetics, Genome, Genetic testing, Knowledge, Disease, Research report, Research, Cancer

The "Metagenomic Markets: Global Market Analysis with Forecasts by Applications, Technologies, Product and User 2024 to 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Metagenomic Markets: Global Market Analysis with Forecasts by Applications, Technologies, Product and User 2024 to 2028" report has been added to ResearchAndMarkets.com's offering.
  • Learn all about it in this new research report.
  • This report looks at the technology, the applications, the users and the types of products that will be sold.
  • Get our research team working for you by ordering all, or a portion, of this comprehensive report.

Exact Sciences Launches Riskguard™ Hereditary Cancer Test in the United States

Retrieved on: 
Wednesday, February 28, 2024
Biotechnology, Health, Biometrics, Other Health, Pharmaceutical, Oncology, Practice Management, Medical Devices, General Health, Hospitals, Genetics, Health Technology, Health Insurance, Medical Supplies, Breast cancer, College, NCI, Multimedia, Physician, Cancer, Food, Prostate, Skin, National Cancer Institute, Risk, Breast, Medicine, CGC, Medicare, Patient, Genetic testing, CLIA, Gene, Kidney, CAP, Exact sciences, Insurance

Exact Sciences Corp., a leading provider of cancer screening and diagnostic tests, today announced the launch of the Riskguard™ hereditary cancer test in the United States.

Key Points: 
  • Exact Sciences Corp., a leading provider of cancer screening and diagnostic tests, today announced the launch of the Riskguard™ hereditary cancer test in the United States.
  • Offering more effective personalized screening solutions supports Exact Sciences’ commitment to help detect cancer earlier.”
    For patients already diagnosed with cancer, knowing about certain gene variants can help create individualized treatment plans for patients.
  • Exact Sciences’ customer care teams are available to help patients explore the testing process and understand possible results and outcomes.
  • The test is processed in Marshfield, WI at PreventionGenetics, an Exact Sciences laboratory qualified to perform high-complexity clinical laboratory testing that has been providing quality genetic testing since 2004 and joined Exact Sciences in 2022.

City of Hope Launches First-of-its-Kind Mobile Cancer Prevention and Screening Program

Retrieved on: 
Monday, February 26, 2024
Biotechnology, Pharmaceutical, Oncology, General Health, Health, Hospitals, Health Technology, Other Health, American Cancer Society, Music, NCI, Multimedia, Education, Cancer, National Cancer Institute, AV, Volunteering, Risk, Death, Practitioner, Vaccine, Virus, Risk assessment, Nursing, Organization, Human resources, Policy, Genetic testing, Patient, Health equity, Research, Entertainment, Mobile phone

City of Hope, one of the largest cancer research and treatment organizations in the United States, is taking leading-edge clinical screening and care into Southern California communities and beyond with the launch of their new mobile cancer prevention and screening program.

Key Points: 
  • City of Hope, one of the largest cancer research and treatment organizations in the United States, is taking leading-edge clinical screening and care into Southern California communities and beyond with the launch of their new mobile cancer prevention and screening program.
  • Cancer screening programs like City of Hope’s can help prevent thousands of additional cancer cases and deaths through early detection.
  • "Our comprehensive mobile cancer prevention and screening program is the next step in our mission to expand access to optimal cancer care, bringing our expertise outside the walls of our campus and into the communities we serve,” said Harlan Levine, president of Health Innovation and Policy at City of Hope.
  • While City of Hope’s mobile cancer prevention and screening program will initially launch in Southern California, the organization has plans to expand these offerings into additional communities of their other City of Hope cancer center locations.

LetsGetChecked Launches myGeneticScreen, a Genetic Testing Service Designed to Deliver Personalized, Actionable Insights into Predisposition for Inherited Cancers and Cardiovascular Diseases

Retrieved on: 
Wednesday, February 21, 2024
Medical Devices, Genetics, Health Technology, Telemedicine, Virtual Medicine, Cardiology, Biotechnology, Health, General Health, Oncology, Genetic counseling, Cardiovascular disease, FACMG, Hereditary nonpolyposis colorectal cancer, Ovarian cancer, Risk, Disease, Patient, Genetic testing, HBOC, Gene, Knowledge, Genomics, CDC, FH, Mortality, Familial hypercholesterolemia, Cancer

LetsGetChecked, a global healthcare solutions company, announced today the launch of myGeneticScreen, a genetic testing service designed to provide patients with valuable and actionable insights into their predisposition for certain hereditary conditions with end-to-end support, including personalized health reports and access to genetic counseling.

Key Points: 
  • LetsGetChecked, a global healthcare solutions company, announced today the launch of myGeneticScreen, a genetic testing service designed to provide patients with valuable and actionable insights into their predisposition for certain hereditary conditions with end-to-end support, including personalized health reports and access to genetic counseling.
  • This addition to LetGetChecked’s genetics portfolio strengthens the company’s commitment to empowering people with accessible health information and care to live longer, happier lives.
  • Using a saliva specimen, myGeneticScreen analyzes 11 genes associated with three conditions recommended by the Centers for Disease Control and Prevention (CDC) as actionable Tier 1 conditions.
  • Offering a best-in-class experience, the genetic testing service includes pre- and post- genetic counseling.

Invitae to Present Data at the 2024 ACMG Annual Clinical Genetics Meeting

Retrieved on: 
Tuesday, March 5, 2024
SAN, VUS, Genotype, Cancer, P572, MSH2, FRCPA, Research, OTC, City, FACMG, Hereditary nonpolyposis colorectal cancer, Medical research, MLH1, PMS2, P22, Disclosure, Arrhythmia, Cardiomyopathy, CGC, RNA, Classification, Infant, Phenotype, American College, Landscape, ACMG, Patient, Genetic testing, Gene, TTN, MMR, Science, Variant, Medical genetics, Laboratory, DNA, Partnership

SAN FRANCISCO, March 5, 2024 /PRNewswire/ -- Researchers from Invitae (OTC: NVTA), a leading medical genetics company, are showcasing their work next week at the 2024 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting in Toronto, Canada from March 12-16. The meeting's clinical agenda will include presentations on both research and clinical topics that promote the science and practice of clinical genetics and genomics.

Key Points: 
  • SAN FRANCISCO, March 5, 2024 /PRNewswire/ -- Researchers from Invitae (OTC: NVTA), a leading medical genetics company, are showcasing their work next week at the 2024 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting in Toronto, Canada from March 12-16.
  • The meeting's clinical agenda will include presentations on both research and clinical topics that promote the science and practice of clinical genetics and genomics.
  • "The ACMG Annual Clinical Genetics Meeting is an incredible opportunity for our researchers and collaborators to highlight ongoing scientific advancements to support genetics-informed patient care," said W. Michael Korn, M.D., chief medical officer at Invitae.
  • Invitae plans to present posters (P164 and P073) about Lynch syndrome and VUS in mismatch repair (MMR) genes and multiplex assays of variant effects (MAVEs).